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Abstract Introduction Chromosome 10q allelic loss
commonly occurs in glioblastoma. Disruption of PTEN, one
of three known 10q tumor suppressor genes, affects the
immune system by increasing tumor expression of immu-
nosuppressive protein B7-H1 and by increasing tumor
release of Th2-inducing cytokines. While the former might
impair antitumor cellular immunity, a consideration for
immunotherapy, the latter could cause 10q-maintaining
tumor patients to experience comparatively higher rates of
bacterial infections, a source of morbidity and mortality in
glioblastoma patients. Methods We retrospectively reviewed
58 glioblastoma patients whose tumors were designated
‘‘normal-10q’’ (n = 16) or ‘‘LOH-10q’’ (n = 42) using loss
of heterozygosity (LOH) assays of microsatellite markers in
constitutional/tumor DNA pairs. Records were reviewed for
symptomatic, microbiologically or radiographically con-
firmed infections in the first 2 years after diagnosis. Results
Infection occurred more frequently in ‘‘normal-10q’’ than
‘‘LOH-10q’’ patients (56% vs. 14% of patients experiencing
infection; P = 0.001). ‘‘Normal-10q’’ patients more com-
monly developed all four infection types studied (urinary
tract = 38% vs. 13%, craniotomy wound = 19% vs. 0%,
pneumonia = 19% vs. 5%, sepsis = 6% vs. 3%). ‘‘Normal-
10q’’ and ‘‘LOH-10q’’ patients had similar survival, ages,
chemotherapy treatment rates, and frequency of patients on
dexamethasone 1 month after radiation therapy (P = 0.4–
0.98), making these factors unlikely to explain the observed
difference in infection rates. Conclusion While tumor
mutations may inhibit antitumor immunity, the effects of
these mutations on systemic immunity remain undeter-
mined. We found higher infection rates after glioblastoma
diagnosis in patients whose tumors maintained chromosome
10q than in patients whose tumors had allelic 10q loss.
Differing effects of this genetic alteration on antitumor and
systemic immunity may warrant further investigation,
potentially providing insight into mechanisms of antitumor
immunity and host defenses against local and systemic
infections.
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Introduction
Three tumor suppressor genes residing on human chro-
mosome 10q (ERCC 6, PTEN, and DMBT1) have been
implicated in the development and progression of several
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types of neoplasms, including astrocytic tumors [1–5]. In
particular, chromosome 10q allelic loss commonly occurs
in glioblastoma, with over 80% of glioblastomas exhibiting
loss of heterozygosity (LOH) for at least one locus on
chromosome 10q [6].
Glioblastoma patients can exhibit impaired antitumor
immunity and impaired systemic immunity leading to
bacterial infections. The former relies on local cellular
immunity mediated by the Th1 subset of helper T cells,
while the latter relies on systemic humoral immunity
mediated by the Th2 subset of helper T cells. These two
types of impaired immunity may occur in different subsets
of glioblastoma patients: two-thirds of glioblastoma
patients have tumor-secreted cytokines that promote a
circulating Th2 profile, while 1/3 favor a Th1 profile [7, 8].
Interestingly, disruption of two of the 3 tumor suppressor
genes found on chromosome 10q may mediate a decrease in
tumor cell immunogenicity, with their loss impairing an
effective cellular host immune response to the tumor. First,
DBMT1 may attract tumor-infiltrating macrophages: its loss
may impair microglial infiltration into gliomas [9]. Second,
disruption of PTEN (phosphatase and tensin homologue
deleted in chromosome 10) may increase expression of
immunosuppressive protein B7-H1 [10] and also increases
Th2-inducing cytokine release [11, 12]. While the former
might impair antitumor cellular immunity in patients with
LOH on chromosome 10q, a consideration for immuno-
therapy, the latter could cause 10q-maintaining tumor
patients to experience increased bacterial infections, a
source of morbidity and mortality in glioblastoma patients.
We investigated the possibility that tumor-specific
mutations in chromosome 10q could define two subsets of
glioblastoma patients, one subset with impaired cellular
antitumor immunity and another with less effective humoral
immunity to systemic infection. Specifically, we sought to
determine if tumor LOH of 10q, which has previously been
shown to impair the cellular immune response to malignant
gliomas [10], might be associated with increased systemic




We retrospectively reviewed 58 glioblastoma patients whose
tumors were classified on the basis of loss of heterozygosity
of 10q (n = 42) or maintained heterozygosity of 10q
(n = 16). Tumor DNA was extracted from microdissected,
formalin-fixed, paraffin-embedded sections; constitutional
DNA was extracted from blood lymphocytes or from
formalin-fixed, paraffin-embedded sections of adjacent,
uninvolved brain or other tissues [13]. Allelic chromosomal
loss was assessed by loss of heterozygosity assays in con-
stitutional DNA/tumor DNA pairs using microsatellite
markers on 10q23-24 (D10S185 and D10S2491, near PTEN)
and 10q25-26 (D10S587) [13]. The tumors reported here are
those among a consecutive series of 140 consecutive newly
diagnosed glioblastomas resected at our institution 1995–
2001 and molecularly analyzed in a previous report [14] for
which sufficient tissue was available to assess for loss of
heterozygosity of 10q. Karnofsky performance score (KPS)
was determined by the neuro-oncologist at the first clinic
visit. We reviewed medical records for the following types of
infections occurring within 2 years of patients’ glioblastoma
diagnosis: (1) symptomatic pneumonia confirmed by chest
X-ray and treated with antibiotics; (2) urinary tract infection
confirmed by suspicious urinalysis or positive urine culture
and treated with antibiotics; (3) craniotomy wound infection
requiring reoperation and/or antibiotics; and (4) blood-borne
infection confirmed by two bottles of blood cultures that
grew an organism and led to antibiotic treatment. This study
was approved by the Institutional Review Board (IRB) at our
institution.
Statistical analysis
Student’s t-test was used for parametric comparisons
between variables. A Mantel–Haenszel analysis was used
to analyze infections in patients with and without LOH 10q
stratified by infection type. A multivariate Cox propor-
tional hazards model was used to analyze infections as a
function of LOH 10q status, age, postoperative chemo-
therapy, and whether a patient was still on dexamethasone
1 month after radiation. Kaplan Meier survival analysis
and the logrank test were used to compare time to infection
in the glioblastoma subgroups. Patients who died without
known infections were censored in this analysis at the time
of death. P values are two-tailed.
Results
Patient characteristics
Patients whose tumors had maintenance versus LOH 10q
had similar profiles when analyzed for parameters that
might influence their rate of systemic infections, including
survival, age at diagnosis, KPS, tumor diameter at diag-
nosis, white blood cell (WBC) count prior to chemotherapy
and radiation, percentage of patients whose tumors were
biopsied versus surgically resected, percentage of patients
receiving postoperative chemotherapy, and percentage of
patients on dexamethasone 1 month after finishing radia-
tion therapy (P = 0.4–0.98) (Table 1).
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Infections
Infections of all kinds were more frequent in patients
whose glioblastomas did not have LOH 10q (56%) com-
pared to patients whose glioblastomas had LOH 10q (14%)
(Fig. 1) (P = 0.001). In terms of specific types of infec-
tions, urinary tract infections (38% vs. 13%, P = 0.03),
craniotomy wound infections (19% vs. 0%, P = 0.004),
pneumonia (19% vs. 5%, P = 0.09), and positive blood
cultures (6% vs. 3%, P = 0.5) were more common in
patients whose glioblastomas did not have LOH 10q
(Fig. 2). A Mantel–Haenszel analysis stratified by infection
type yielded an odds ratio of 4.2 (95% CI = 1.4–12.4) for
infection in patients whose tumors did not have LOH 10q
compared to those whose tumors did (P = 0.0002). A Cox
proportional hazards model revealed that infection of any
type was significantly predicted by lack of LOH 10q
(Hazard Ratio = 4.6; P = 0.002) and by dexamethasone
use 1 month after radiation therapy (Hazard Ratio = 1.9;
P = 0.003); age, postoperative chemotherapy, KPS, tumor
diameter, WBC count prior to chemotherapy and radiation,
and use of resection rather than biopsy were not signifi-
cantly predictive of infection of any type (Table 2).
Admission with infection
Patients whose tumors maintained 10q were admitted to the
hospital with infection more frequently (38%) than those
whose tumors had LOH 10q (5%) (P = 0.001) (Fig. 3).
Total hospital days for these admissions were 43 days for
patients whose glioblastomas maintained 10q compared to
23 days for patients whose glioblastomas had LOH 10q,
with a mean of 6 days per admission.
Time to infection
Patients with glioblastomas that maintained 10q developed
infection sooner after glioblastoma diagnosis than patients
whose glioblastomas exhibited LOH 10q (Fig. 4; logrank
P = 0.0002).
Discussion
While tumor mutations may inhibit the host antitumor cel-
lular immune response, the effects of these mutations on host
Table 1 Clinical findings in
patients whose glioblastomas
exhibited maintenance versus
loss of heterozygosity (LOH) of
chromosome 10q
KPS Karnofsky performance
score, WBC white blood cell
Maintained 10q (n = 16) LOH 10q (n = 42) P value
Median survival 476 days 438 days 0.98
Mean age 52 years 54 years 0.6
Median KPS 80 80 0.7
Mean tumor diameter 5.8 cm 5.5 cm 0.6
Mean WBC count prior to chemotherapy
and radiation
6.5 9 109 cells/l 6.8 9 109 cells/l 0.7




































Fig. 1 Percentage of patients with infection during the 2 years after
being diagnosed with a glioblastoma in which there was maintenance






































Fig. 2 Percentage of patients with glioblastomas exhibiting maintenance
(black) versus loss of heterozygosity (LOH) of chromosome 10q (white)
who had infections of various types, including urinary tract infections,
craniotomy wound infections, pneumonia, and positive blood cultures
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immunity to systemic infections remain undetermined. We
found that loss of heterozygosity of 10q, a glioblastoma
mutation that may reduce antitumor cellular immunity, is also
associated with less frequent systemic infections, suggesting
a nonspecifically enhanced humoral immunity relative to
patients who harbor glioblastomas maintaining 10q.
The rates of systemic infections in our glioblastoma
patients are comparable to those reported elsewhere. We
reported a 13% overall rate of hospitalization with infection
during the 2 years after glioblastoma diagnosis, while
another report described a 9% rate of hospitalization for
glioblastoma patients during the 6 weeks of radiotherapy
[15]. Another study reported a 4% wound infection rate
with craniotomies in general [16]. Thus, our overall wound
infection rate of 5% is not unreasonable considering the
immunosuppressed state of glioblastoma patients.
Three tumor suppressor genes residing on human chro-
mosome 10q (ERCC 6, PTEN, and DMBT1) have been
implicated in the development and progression of several
types of neoplasms, including astrocytic tumors. Chromo-
some 10q allelic loss commonly occurs in glioblastoma,
with over 80% of glioblastomas exhibiting loss of hetero-
zygosity (LOH) for at least one locus on chromosome 10q
[6], a far more common alteration than alterations in any of
the three individual oncogenes residing on 10q. For
example, PTEN alterations are seen in 30–44% of glio-
blastomas [17]. Thus, our findings suggest that there is a
reduced rate of systemic infections in patients whose
glioblastomas exhibit alterations of one or more of these
three oncogene(s) on chromosome 10q.
Interestingly, two of the three known tumor suppressor
genes found on chromosome 10q may mediate a cellular
antitumor immune response, with their loss impairing this
response. First, DMBT1 is a candidate tumor suppressor
for brain, gastrointestinal, and lung cancer, although one
study found that DMBT1 homozygous deletions in 10
glioblastomas with 10q LOH reflected unmasking of con-
stitutional deletion polymorphisms by the 10q loss [18].
DMBT1 belongs to the superfamily of scavenger receptor
cysteine-rich proteins, is produced by both tumor-associ-
ated macrophages and tumor cells, and appears to attract
tumor-infiltrating macrophages, allowing its loss to
potentially impair microglial infiltration into gliomas [9].
Second, disruption of PTEN, an inhibitor of the PI3 kinase
signaling pathway, may increase expression of immuno-
suppressive protein B7-H1 [10] and increases Th2-
inducing cytokine release [11, 12].
Glioblastoma patients can exhibit impaired antitumor
immunity and impaired systemic immunity leading to
Table 2 Results of multivariate
logistic regression on factors
predicting infection of any type
during the first 2 years after
glioblastoma diagnosis
Factor Hazard ratio (95% CI) P value
No LOH 10q 4.7 (3.2–5.5) 0.002
Postoperative chemotherapy 2.2 (0.4–14.2) 0.4
On dexamethasone 1 month after
radiation therapy
2.0 (1.1–2.6) 0.003
Age 1.1 per decade (0.6–1.4) 0.7
KPS 0.8 per 10 point increase (0.6–1.1) 0.6
Tumor diameter 1.1 per cm diameter (0.7–1.5) 0.8
WBC count prior to chemotherapy
and radiation
0.9 per 109 WBCs/l (0.6–1.2) 0.8







































Fig. 3 Percentage of patients with glioblastomas exhibiting mainte-
nance (black) versus loss of heterozygosity (LOH) of chromosome
10q (white) who were readmitted to the hospital with infection
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Fig. 4 Time from glioblastoma diagnosis until infection in days for
patients whose tumors exhibited maintenance (solid line) versus LOH
10q (dashed line)
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bacterial infections. The former relies on local cellular
immunity mediated by the Th1 subset of helper T cells,
while the latter relies on systemic humoral immunity
mediated by the Th2 subset of helper T cells. These two
types of impaired immunity may occur in different subsets
of glioblastoma patients. Of note, two-thirds of glioblas-
toma patients have tumor-secreted cytokines that favor a
circulating Th2 profile, while 1/3 of glioblastomas secrete
cytokines favoring a Th1 profile [7, 8]. One study found that
most glioblastoma patients have both elevated circulating
levels of interleukin 10, a Th2 promoting cytokine, and
reduced circulating interleukin 12, a Th1 promoting
cytokine, and that the changes were independent of corti-
costeroid usage [19]. A similar report found that the Th1-
promoting cytokines tumor necrosis factor (TNF) a and
interferon (IFN) gamma were reduced in peripheral lym-
phocytes and glioma cell cultures compared to controls, and
that the Th2 promoting cytokines interleukin 4 and inter-
leukin 10 were elevated in peripheral lymphocytes and
glioma cell cultures compared to controls [20]. In addition
to the roles of these cytokines in maintaining the Th2 profile
in the majority of glioma patients, others have found that an
increased regulatory T cell fraction causes this Th2 profile
[21]. In some tumor types, Th1 cells are tumoricidal via a
FasL-Fas interaction, while Th2 cells promote tumor
growth [22], underscoring the ability of the two helper T
cell types to exert opposite effects on tumors. The obser-
vations that glioblastoma patients who experience
postoperative cranial wound infections exhibit longer sur-
vival [23, 24] and that postoperative empyema prolongs
survival in bronchogenic carcinoma patients [25, 26] have
been attributed to bacterial lipopolysaccharide (LPS) elic-
iting a nonspecific immune response a portion of which
targets the tumor [27, 28] or to these infections causing an
immune cell infiltrate at the tumor resection site which
promotes a specific cross-reactive immunological attack
against the tumor. However, our findings also raise the
possibility that tumor mutations might stratify patients into
two groups with different circulating helper T cell pro-
files—those with more potent antitumor Th1-mediated
cellular immunity capable of limiting tumor growth may
also have weaker Th2-mediated humoral immunity ren-
dering them more prone to infections, while patients whose
tumor mutations lead to a circulating Th2 profile might
ward off infection effectively but be unable to mount a
cellular immune response against the tumor.
We hypothesize that our finding that patients whose
glioblastomas exhibited LOH 10q exhibited a reduced fre-
quency of systemic infections reflected a circulating Th2
versus Th1 profile. Our study was an initial study designed
to address a different hypothesis, that patients whose glio-
blastomas exhibiting LOH 10q would exhibit a reduced
frequency of systemic infections. Future studies will need to
overcome limitations of our study, which include its retro-
spective nature and somewhat smaller sample size. The
hypothesis that we verified in our retrospective series will
first require verification by prospective analysis in larger
series. Such studies could also address other questions by
investigating the circulating helper T cell profile in a large
number of glioblastoma patients and correlating it with, not
just tumoral 10q status, the parameter analyzed in our
report, but with mutations in each of the three specific 10q
oncogenes, and with the subsequent development of clinical
infections. If our data is elaborated upon in this manner, the
fact that the majority of glioblastomas exhibit LOH 10q
could explain why the majority of glioblastoma patients
exhibit a circulating Th2 rather than Th1 profile, one that
promotes humoral immunity against systemic infection but
weakens cellular antitumor immunity [19]. Further inves-
tigation of the different effects of an oncogene mutation on
antitumor cellular versus systemic humoral immunity could
provide insight into both antitumor immunity and host
defenses against local and systemic infection. Such insight
may help identify glioblastoma patients who might benefit
most from immunotherapy or patients who might need
greater antibiotic prophylaxis, and might eventually lead to
ways of stimulating antitumor immunity while protecting
glioblastoma patients from infection-induced morbidity and
mortality.
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